Targeting NaV1.7 Sodium Channels Through CRMP2 SUMOylation Inhibition: Clinical Implications of t-CSM

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

The voltage-gated sodium channel NaV1.7, encoded by the SCN9A gene, plays a critical role in nociception. Mutations in SCN9A have illustrated the clinical relevance of this channel: loss-of-function variants result in congenital insensitivity to pain (CIP), while gain-of-function variants drive pathological hyperexcitability, as seen in erythromelalgia and other neuropathic pain syndromes.

Therapeutically, selectively inhibiting NaV1.7 without interfering with other sodium channels has been an enduring challenge due to the structural similarity across the NaV channel family. A novel approach involves targeting upstream regulatory mechanisms of NaV1.7 trafficking rather than directly binding to the channel pore itself.

Challenges in Developing NaV1.7 Blockers

Attempts to design NaV1.7-selective antagonists have been limited by the high degree of structural homology with other sodium channels, including NaV1.1–NaV1.9. Off-target inhibition produces unacceptable toxicities due to their essential roles in the central nervous system, cardiac conduction, and muscle contraction. Even compounds with high NaV1.7 selectivity ratios fail to achieve sufficient inhibition without dose-limiting side effects.

Indirect Modulation Through CRMP2 SUMOylation

An alternative strategy bypasses direct channel binding. The t-CSM peptide modulates NaV1.7 activity by disrupting the CRMP2–Ubc9 protein interaction, thereby preventing SUMOylation of CRMP2 at lysine 374. This modification regulates the trafficking of NaV1.7 to the neuronal membrane. Disrupting this process reduces NaV1.7 current density without altering other sodium channels.

Selectivity of CRMP2 SUMOylation Inhibition

• Lack of effect on other NaV isoforms: Experimental data show selective reduction of NaV1.7 trafficking, with no impact on NaV1.1, NaV1.3, NaV1.5, NaV1.6, NaV1.8, or NaV1.9.
• Cardiac safety profile: No measurable effect on NaV1.5 sodium currents was observed, even in cardiac cell models with Ubc9 overexpression.
• Calcium channel preservation: Calcium influx in sensory neurons remained unaffected, confirming pathway specificity.

Functional Impact on Pain Signaling

In preclinical models, inhibition of CRMP2 SUMOylation decreased NaV1.7 nociceptor firing by approximately 80%, surpassing the efficacy achievable with direct antagonists. Immunofluorescence assays demonstrated a marked reduction in NaV1.7 surface localization within dorsal root ganglion (DRG) neurons.

Importantly, administration of t-CSM reversed mechanical and thermal hypersensitivity in models of spinal nerve injury without inducing motor deficits or sedation, supporting its safety profile. Effects persisted for up to 24 hours post-administration.

Clinical Translation Potential

The CRMP2 SUMOylation pathway is conserved in human sensory neurons, supporting the likelihood of translational success. Elevated CRMP2 SUMOylation has been observed in chronic neuropathic states, correlating with NaV1.7 upregulation. Preventing this modification appears to normalize nociceptor hyperexcitability.

Molecular Design and Mechanism

t-CSM is a tat-conjugated cell-penetrating peptide incorporating CRMP2’s SUMO motif sequence. The structure enables intracellular delivery and specific disruption of CRMP2–Ubc9 binding. Computational modeling identified key interaction residues between CRMP2 and Ubc9, which guided rational peptide design.

Amino acid sequence:

• Cell-penetrating domain (tat): YGRKKRRQRRR
• CRMP2 SUMO motif-derived sequence: GKMDENQ

This construct selectively interferes with NaV1.7 trafficking while sparing other SUMO-dependent cellular processes, avoiding the systemic toxicity that would arise from inhibiting Ubc9 globally.

Conclusion

The development of t-CSM represents a significant advance in pain therapeutics. By indirectly modulating NaV1.7 trafficking through selective inhibition of CRMP2 SUMOylation, this strategy achieves potent nociceptor suppression while avoiding the off-target toxicities that have hindered prior NaV1.7 antagonists.

This targeted protein–protein interaction approach introduces a promising new paradigm in the search for non-addictive, safe, and effective treatments for chronic pain.

REFERENCES

1. François-Moutal, L., Dustrude, E. T., Wang, Y., Brustovetsky, T., Dorame, A., Ju, W., Moutal, A., Perez-Miller, S., Brustovetsky, N., Gokhale, V., Khanna, M., & Khanna, R. (2018). Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. Pain, 159(10), 2115–2127. https://doi.org/10.1097/j.pain.0000000000001294
2. Dustrude, E. T., Perez-Miller, S., François-Moutal, L., Moutal, A., Khanna, M., & Khanna, R. (2017). A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. Channels (Austin, Tex.), 11(4), 316–328. https://doi.org/10.1080/19336950.2017.1299838
3. Wang, L., Ji, S. Inhibition of Ubc9-Induced CRMP2 SUMOylation Disrupts Glioblastoma Cell Proliferation. J Mol Neurosci 69, 391–398 (2019). https://doi.org/10.1007/s12031-019-01368-y
4. Dustrude, E. T., Wilson, S. M., Ju, W., Xiao, Y., & Khanna, R. (2013). CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking. The Journal of biological chemistry, 288(34), 24316–24331. https://doi.org/10.1074/jbc.M113.474924
5. François-Moutal, L., Scott, D. D., Perez-Miller, S., Gokhale, V., Khanna, M., & Khanna, R. (2018). Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels. Channels (Austin, Tex.), 12(1), 219–227. https://doi.org/10.1080/19336950.2018.1491244